Levetiracetam

Key Product Details

Product Description

Levetiracetam is an antiepileptic that displays distinctive properties from conventional antiepileptic drugs. Displays potent seizure protection in animal models of chronic epilepsy but lacks activity in acute seizure models. Binds synaptic vesicle protein 2A (SV2A) and inhibits Na⁺-dependent Cl^-/HCO₃^- exchange. In a mouse model of Alzheimer's disease, Levetiracetam rescues levels of presynaptic vesicle fusion and neurotransmitter release, reduces Aβ42 and APP levels and decreases deposits of amyloid plaque; in vitro Levetiracetam inhibits Aβ-induced glutamate from astrocytes.

Product Specifications for Levetiracetam

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Levetiracetam

The following data is based on the product molecular weight 170.21.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	5.88 mL	29.38 mL	58.75 mL
5 mM	1.18 mL	5.88 mL	11.75 mL
10 mM	0.59 mL	2.94 mL	5.88 mL
50 mM	0.12 mL	0.59 mL	1.18 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 6 publications citing the usage of this product.

• Rao and Savas Levetiracetam treatment normalizes levels of presynaptic endocytosis machinery and restores nonamyloidogenic APP processing in App knock-in mice J.Proteome Res. 2021 PMID: 34106705
• Sanz-Blasco Levetiracetam inhibits oligomeric Aβ-induced glutamate release from human astrocytes. Neuroreport 2016 PMID: 27183239
• Sanchez Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc.Natl.Acad.Sci. USA 2012 PMID: 22869752
• Lynch The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug LeveT. Proct.Natl.Acad.Sci. USA 2004 PMID: 15210974
• Ueda Effect of LeveT on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl₃ injection. Brain Res. 2007 PMID: 17408599
• Smedt LeveT: the profile of a novel anticonvulsant drug - part I: preclinical data. CNS Drug Rev. 2007 PMID: 17461889

Product Documents for Levetiracetam